Media stories about NxStage Medical (NASDAQ:NXTM) have trended somewhat positive on Sunday, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. NxStage Medical earned a news sentiment score of 0.08 on Accern’s scale. Accern also gave news stories about the medical device company an impact score of 47.0314982195607 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

A number of research analysts have recently issued reports on the company. Leerink Swann downgraded NxStage Medical from an “outperform” rating to a “market perform” rating and lifted their price target for the company from $28.00 to $30.00 in a report on Tuesday, August 22nd. BTIG Research downgraded NxStage Medical from a “buy” rating to a “neutral” rating in a research note on Friday, August 11th. Zacks Investment Research downgraded NxStage Medical from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. Stephens downgraded NxStage Medical from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $33.00 to $30.00 in a research note on Wednesday, August 9th. Finally, Jefferies Group LLC downgraded NxStage Medical from a “buy” rating to a “hold” rating and dropped their target price for the stock from $33.00 to $30.00 in a research note on Tuesday, August 8th. One research analyst has rated the stock with a sell rating and nine have assigned a hold rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $30.25.

Shares of NxStage Medical (NXTM) traded down 0.22% during trading on Friday, hitting $27.79. The stock had a trading volume of 983,106 shares. The stock’s 50-day moving average is $27.58 and its 200-day moving average is $25.90. The stock’s market cap is $1.83 billion. NxStage Medical has a 12-month low of $20.45 and a 12-month high of $30.80.

NxStage Medical (NASDAQ:NXTM) last announced its quarterly earnings data on Monday, August 7th. The medical device company reported ($0.03) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.03). The firm had revenue of $92.20 million during the quarter, compared to the consensus estimate of $96.47 million. NxStage Medical had a negative net margin of 1.33% and a negative return on equity of 2.43%. The firm’s revenue was up .0% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.03) earnings per share. On average, equities research analysts expect that NxStage Medical will post ($0.05) EPS for the current year.

In other news, President Joseph E. Turk, Jr. sold 24,000 shares of NxStage Medical stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $29.64, for a total transaction of $711,360.00. Following the completion of the sale, the president now directly owns 82,903 shares in the company, valued at approximately $2,457,244.92. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, President Joseph E. Turk, Jr. sold 1,000 shares of NxStage Medical stock in a transaction that occurred on Wednesday, July 5th. The shares were sold at an average price of $25.19, for a total transaction of $25,190.00. Following the sale, the president now owns 75,903 shares of the company’s stock, valued at $1,911,996.57. The disclosure for this sale can be found here. In the last 90 days, insiders sold 50,400 shares of company stock valued at $1,386,536. 4.70% of the stock is owned by insiders.

COPYRIGHT VIOLATION NOTICE: “NxStage Medical (NXTM) Receiving Somewhat Positive Press Coverage, Study Finds” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of US & international copyright laws. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/17/nxstage-medical-nxtm-receiving-somewhat-positive-press-coverage-study-finds.html.

NxStage Medical Company Profile

NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.

Insider Buying and Selling by Quarter for NxStage Medical (NASDAQ:NXTM)

Receive News & Stock Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related stocks with our FREE daily email newsletter.